Design Therapeutics (DSGN) Operating Expenses (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Operating Expenses of $22.2 million for Q2 2026, up 2.82% year-over-year from $21.6 million in Q2 2025, and up 12.54% on a QoQ basis from $19.7 million in Q1 2026.
Design Therapeutics (DSGN) Operating Expenses (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $22.2 million in Q2 2026.
- Operating Expenses for Q2 2026 came in at $22.2 million, up 2.82% year-over-year; the trailing twelve-month figure through Jun 2026 was $79.4 million (up 5.92% YoY), and the FY2025 annual result was $79.5 million, up 27.39% from the prior year.
- Operating Expenses climbed to $22.2 million in Q2 2026, from $19.7 million in the prior quarter.
- Over five years, Operating Expenses peaked at $22.6 million in Q2 2023 and troughed at $13.4 million in Q1 2022.
- A 5-year average of $18.3 million and a median of $19.0 million in 2022 frame the typical range for Operating Expenses.
- The widest annual swing landed in 2022, when Operating Expenses soared 135.39%; it then plunged 33.49% in 2024.
- A 5-year view of Operating Expenses shows it stood at $19.4 million in 2022, then declined by 22.02% to $15.1 million in 2023, then gained by 10.4% to $16.7 million in 2024, then grew by 8.84% to $18.2 million in 2025, then advanced by 22.06% to $22.2 million in 2026.
- Per Business Quant data, the three most recent Operating Expenses figures were $22.2 million in Q2 2026, $19.7 million in Q1 2026, and $18.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 22.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.18 Mn |
| Mar 31, 2026 | 19.71 Mn |
| Dec 31, 2025 | 18.17 Mn |
| Sep 30, 2025 | 19.31 Mn |
| Jun 30, 2025 | 21.57 Mn |
| Mar 31, 2025 | 20.42 Mn |
| Dec 31, 2024 | 16.69 Mn |
| Sep 30, 2024 | 16.25 Mn |
| Jun 30, 2024 | 15.04 Mn |
| Mar 31, 2024 | 14.40 Mn |
| Dec 31, 2023 | 15.12 Mn |
| Sep 30, 2023 | 18.82 Mn |
| Jun 30, 2023 | 22.60 Mn |
| Mar 31, 2023 | 21.65 Mn |
| Dec 31, 2022 | 19.39 Mn |
| Sep 30, 2022 | 19.19 Mn |
| Jun 30, 2022 | 15.64 Mn |
| Mar 31, 2022 | 13.37 Mn |
| Dec 31, 2021 | 11.13 Mn |
| Sep 30, 2021 | 11.34 Mn |